<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35963600</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-7780</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</Title><ISOAbbreviation>J Infect Chemother</ISOAbbreviation></Journal><ArticleTitle>Post COVID-19 condition of the Omicron variant of SARS-CoV-2.</ArticleTitle><Pagination><StartPage>1546</StartPage><EndPage>1551</EndPage><MedlinePgn>1546-1551</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jiac.2022.08.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1341-321X(22)00233-1</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To investigate the prevalence of post coronavirus disease (COVID-19) condition of the Omicron variant in comparison to other strains.</AbstractText><AbstractText Label="STUDY DESIGN">A single-center cross-sectional study.</AbstractText><AbstractText Label="METHODS">Patients who recovered from Omicron COVID-19 infection (Omicron group) were interviewed via telephone, and patients infected with other strains (control group) were surveyed via a self-reporting questionnaire. Data on patients' characteristics, information regarding the acute-phase COVID-19, as well as presence and duration of COVID-19-related symptoms were obtained. Post COVID-19 condition in this study was defined as a symptom that lasted for at least 2 months, within 3 months of COVID-19 onset. We investigated and compared the prevalence of post COVID-19 condition in both groups after performing propensity score matching.</AbstractText><AbstractText Label="RESULTS">We conducted interviews for 53 out of 128 patients with Omicron and obtained 502 responses in the control group. After matching cases with controls, 18 patients from both groups had improved covariate balance of the factors: older adult, female sex, obesity, and vaccination status. There were no significant differences in the prevalence of each post COVID-19 condition between the two groups. The number of patients with at least one post COVID-19 condition in the Omicron and control groups were 1 (5.6%) and 10 (55.6%) (p&#xa0;=&#xa0;0.003), respectively.</AbstractText><AbstractText Label="CONCLUSIONS">The prevalence of post Omicron COVID-19 conditions was less than that of the other strains. Further research with a larger sample size is needed to investigate the precise epidemiology of post COVID-19 condition of Omicron, and its impact on health-related quality of life and social productivity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morioka</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan. Electronic address: shmorioka@hosp.ncgm.go.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuzuki</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AMR Clinical Reference Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terada</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akashi</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osanai</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuge</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanada</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruki</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayakawa</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teruya</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>AIDS Clinical Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hojo</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, National Center for Global Health and Medicine Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohmagari</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Infect Chemother</MedlineTA><NlmUniqueID>9608375</NlmUniqueID><ISSNLinking>1341-321X</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">Post COVID-19 conditions</Keyword><Keyword MajorTopicYN="N">WHO definition</Keyword></KeywordList><CoiStatement>Declaration of competing interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>13</Day><Hour>19</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35963600</ArticleId><ArticleId IdType="pmc">PMC9365517</ArticleId><ArticleId IdType="doi">10.1016/j.jiac.2022.08.007</ArticleId><ArticleId IdType="pii">S1341-321X(22)00233-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization COVID-19 Dashboard. https://www.gavi.org/covid19/dashboard?gclid=CjwKCAjwjtOTBhAvEiwASG4bCJqe6lbmoeoTy14wqJZsAW52-Jqd7HdYU4UUK7-IeVE8zEtoA3hmYxoCkG8QAvD_BwE</Citation></Reference><Reference><Citation>Huang L., Yao Q., Gu X., Wang Q., Ren L., Wang Y., et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747&#x2013;758. doi: 10.1016/s0140-6736(21)01755-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Coronavirus disease (COVID-19): post COVID-19 condition. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  Long COVID or post-COVID conditions. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html#:&#x223c;:text=Health%20conditions&amp;text=Some%20people%2C%20especially%20those%20who,kidney%2C%20skin%2C%20and%20brain</Citation></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/s0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C., Valdes A.M., Polidori L., Antonelli M., Penamakuri S., Nogal A., et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399:1618&#x2013;1624. doi: 10.1016/s0140-6736(22)00327-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(22)00327-0</ArticleId><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization WHO coronavirus Dashboard. https://covid19.who.int/</Citation></Reference><Reference><Citation>World Health Organization Weekly epidemiological update on COVID-19. 15 February 2022. https://reliefweb.int/sites/reliefweb.int/files/resources/20220215_Weekly_Epi_Update_79.pdf</Citation></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Rio C., Collins L.F., Malani P. Long-term health consequences of COVID-19. JAMA. 2020;324:172&#x2013;174. doi: 10.1001/jama.2020.19719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.19719</ArticleId><ArticleId IdType="pmc">PMC8019677</ArticleId><ArticleId IdType="pubmed">33031513</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E., Janvier P., Kherabi Y., Le Bot A., Hamon A., Gouze H., et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81:e4&#x2013;6. doi: 10.1016/j.jinf.2020.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Kim S.S., Lindsell C.J., Rose E.B., Shapiro N.I., Files D.C., et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. MMWR (Morb Mortal Wkly Rep) 2020;69:993&#x2013;998. doi: 10.15585/mmwr.mm6930e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad I., Rathore F.A. Neurological manifestations and complications of COVID-19: a literature review. J Clin Neurosci. 2020;77:8&#x2013;12. doi: 10.1016/j.jocn.2020.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2020.05.017</ArticleId><ArticleId IdType="pmc">PMC7200361</ArticleId><ArticleId IdType="pubmed">32409215</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Penfold R.S., Merino J., Sudre C.H., Molteni E., Berry S., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22:43&#x2013;55. doi: 10.1016/s1473-3099(21)00460-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazato Y., Morioka S., Tsuzuki S., Akashi M., Osanai Y., Tanaka K., et al. Prolonged and late-onset symptoms of coronavirus disease 2019. Open Forum Infect Dis. 2020;7 doi: 10.1093/ofid/ofaa507. ofaa507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa507</ArticleId><ArticleId IdType="pmc">PMC7665672</ArticleId><ArticleId IdType="pubmed">33230486</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho D., Imai K., King G., Stuart E.A. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Software. 2011;42:1&#x2013;28. doi: 10.18637/jss.v042.i08.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v042.i08</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  SARS-CoV-2 variant classifications and definitions. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html</Citation></Reference><Reference><Citation>Shrotri M., Navaratnam A.M.D., Nguyen V., Byrne T., Geismar C., Fragaszy E., et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021;398:385&#x2013;387. doi: 10.1016/s0140-6736(21)01642-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)01642-1</ArticleId><ArticleId IdType="pmc">PMC8285117</ArticleId><ArticleId IdType="pubmed">34274038</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui K.P.Y., Ho J.C.W., Cheung M.-C., Ng K.-C., Ching R.H.H., Lai K.-L., et al. SARS-CoV-2 omicron variant replication in human bronchus and lung ex vivo. Nature. 2022;603:715&#x2013;720. doi: 10.1038/s41586-022-04479-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04479-6</ArticleId><ArticleId IdType="pubmed">35104836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health, Labour and Welfare  Number of domestic cases of variants of SARS-CoV-2 of concern by prefecture (genomic analysis) https://www.mhlw.go.jp/stf/seisakunitsuite/newpage_00054.html</Citation></Reference><Reference><Citation>Our World in data. Coronavirus pandemic (COVID-19) https://ourworldindata.org/coronavirus</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>